Clinical trial
Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects
NCT00121979 · Pharmasset, Industry · Completed
Key facts
| NCT number | NCT00121979 |
|---|---|
| Title | Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects |
| Official title | Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Exploring the Safety, Tolerability, and Antiviral Effect of Substituting 600 mg Racivir for 3TC in HIV-Infected Subjects Who Have the M184V Mutation and Are Currently Failing on a HAART Regimen Containing Lamivudine |
| Lead sponsor | Pharmasset, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Racivir, a non-nucleoside reverse transcriptase inhibitor |
| Enrollment | 60 |
| Start date | Sep 1, 2004 |
| Completion | Mar 1, 2006 |
| First posted | Jul 21, 2005 |
| Last update posted | Jul 3, 2007 |
| Countries | Argentina, Mexico, Panama, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: